Hypoxia signaling: Challenges and opportunities for cancer therapy

dc.contributor.authorIvan, Mircea
dc.contributor.authorFishel, Melissa L.
dc.contributor.authorTudoran, Oana M.
dc.contributor.authorPollok, Karen E.
dc.contributor.authorWu, Xue
dc.contributor.authorSmith, Paul J.
dc.contributor.departmentMicrobiology and Immunology, School of Medicine
dc.date.accessioned2024-06-10T17:34:25Z
dc.date.available2024-06-10T17:34:25Z
dc.date.issued2022-10
dc.description.abstractHypoxia is arguably the first recognized cancer microenvironment hallmark and affects virtually all cellular populations present in tumors. During the past decades the complex adaptive cellular responses to oxygen deprivation have been largely elucidated, raising hope for new anti cancer agents. Despite undeniable preclinical progress, therapeutic targeting of tumor hypoxia is yet to transition from bench to bedside. This review focuses on new pharmacological agents that exploit tumor hypoxia or interfere with hypoxia signaling and discusses strategies to maximize their therapeutic impact.
dc.eprint.versionAuthor's manuscript
dc.identifier.citationIvan, M., Fishel, M. L., Tudoran, O. M., Pollok, K. E., Wu, X., & Smith, P. J. (2022). Hypoxia signaling: Challenges and opportunities for cancer therapy. Seminars in Cancer Biology, 85, 185–195. https://doi.org/10.1016/j.semcancer.2021.10.002
dc.identifier.urihttps://hdl.handle.net/1805/41349
dc.language.isoen_US
dc.publisherElsevier
dc.relation.isversionof10.1016/j.semcancer.2021.10.002
dc.relation.journalSeminars in Cancer Biology
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectHypoxia
dc.subjectHIF1
dc.subjectHIF2
dc.subjectHIF inhibitors
dc.subjectHypoxia-activated prodrug
dc.titleHypoxia signaling: Challenges and opportunities for cancer therapy
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Ivan2022Hypoxia-AAM.pdf
Size:
1.28 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: